"Ve studii \u00FA\u010Dinnosti a p\u0159e\u017Eit\u00ED (studie EPHESUS) byl pacient\u016Fm se srde\u010Dn\u00EDm selh\u00E1n\u00EDm po prod\u011Blan\u00E9m akutn\u00EDm infarktu myokardu pod\u00E1v\u00E1n eplerenon. Celkov\u00E1 incidence ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F zaznamenan\u00E1 ve\u00A0skupin\u011B l\u00E9\u010Den\u00E9 eplerenonem (78,9 %) byla srovnateln\u00E1 s\u00A0incidenc\u00ED ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F ve skupin\u011B s placebem (79,5 %). K\u00A0p\u0159eru\u0161en\u00ED l\u00E9\u010Dby v\u00A0d\u016Fsledku vzniku ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F do\u0161lo u 4,4 % pacient\u016F ve skupin\u011B u\u017E\u00EDvaj\u00EDc\u00ED eplerenon a u 4,3 % pacient\u016F ve skupin\u011B u\u017E\u00EDvaj\u00EDc\u00ED placebo.\nN\u00ED\u017Ee uveden\u00E9 ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky vypl\u00FDvaj\u00ED bu\u010F z v\u00FDsledk\u016F studie EPHESUS - jedn\u00E1 se o ty, u nich\u017E existuje pravd\u011Bpodobn\u00E1 p\u0159\u00ED\u010Dinn\u00E1 souvislost s\u00A0l\u00E9\u010Dbou nebo jsou z\u00E1va\u017En\u00E9 a jejich\u017E incidence byla v\u00FDznamn\u011B vy\u0161\u0161\u00ED ve skupin\u011B l\u00E9\u010Den\u00E9 eplerenonem v\u00A0porovn\u00E1n\u00ED se skupinou u\u017E\u00EDvaj\u00EDc\u00ED\u00A0placebo, nebo byly pozorov\u00E1ny po uveden\u00ED p\u0159\u00EDpravku na trh. Ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky jsou uvedeny po org\u00E1nov\u00FDch syst\u00E9mech a s\u00A0absolutn\u00ED frekvenc\u00ED. Frekvence v\u00FDskytu je definov\u00E1na jako: \u010Dast\u00E1 (\u2265 1/100 a\u017E < 1/10), m\u00E9n\u011B \u010Dast\u00E1 (\u2265 1/1000 a\u017E < 1/100) a nen\u00ED zn\u00E1mo (z dostupn\u00FDch \u00FAdaj\u016F nelze ur\u010Dit) .\nInfekce a infestace\nM\u00E9n\u011B \u010Dast\u00E9: pyelonefritida\nPoruchy krve a lymfatick\u00E9ho syst\u00E9mu\nM\u00E9n\u011B \u010Dast\u00E9: eozinofilie\nPoruchy metabolismu a v\u00FD\u017Eivy\n\u010Cast\u00E9: hyperkalemie\nM\u00E9n\u011B \u010Dast\u00E9: hyponatremie, dehydratace, hypercholesterolemie, hypertriglyceridemie\nPsychiatrick\u00E9 poruchy\nM\u00E9n\u011B \u010Dast\u00E9: nespavost\nPoruchy nervov\u00E9ho syst\u00E9mu\n\u010Cast\u00E9 : z\u00E1vrat\u011B\nM\u00E9n\u011B \u010Dast\u00E9: bolesti hlavy\nSrde\u010Dn\u00ED poruchy\nM\u00E9n\u011B \u010Dast\u00E9: infarkt myokardu, levostrann\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED, fibrilace s\u00EDn\u00ED\nC\u00E9vn\u00ED poruchy\n\u010Cast\u00E9 : hypotenze\nM\u00E9n\u011B \u010Dast\u00E9: arteri\u00E1ln\u00ED tromb\u00F3za doln\u00EDch kon\u010Detin, postur\u00E1ln\u00ED hypotenze\nRespira\u010Dn\u00ED, hrudn\u00ED a mediastin\u00E1ln\u00ED poruchy\nM\u00E9n\u011B \u010Dast\u00E9: faryngitida\nGastrointestin\u00E1ln\u00ED poruchy\n\u010Cast\u00E9 : pr\u016Fjem, nausea\nM\u00E9n\u011B \u010Dast\u00E9: zvracen\u00ED, flatulence\nPoruchy k\u016F\u017Ee a podko\u017En\u00ED tk\u00E1n\u011B\n\u010Cast\u00E9 : vyr\u00E1\u017Eka\nM\u00E9n\u011B \u010Dast\u00E9: sv\u011Bd\u011Bn\u00ED, zv\u00FD\u0161en\u00E9 pocen\u00ED\nNezn\u00E1m\u00E1 frekvence : angioneurotick\u00FD ed\u00E9m\nPoruchy svalov\u00E9 a kostern\u00ED soustavy a pojivov\u00E9 tk\u00E1n\u011B \nM\u00E9n\u011B \u010Dast\u00E9: bolest zad, k\u0159e\u010De doln\u00EDch kon\u010Detin\nPoruchy ledvin a mo\u010Dov\u00FDch cest\n\u010Cast\u00E9 : abnorm\u00E1ln\u00ED funkce ledvin\nPoruchy reproduk\u010Dn\u00EDho syst\u00E9mu a prsu: \nM\u00E9n\u011B \u010Dast\u00E9 : gynekomastie\nCelkov\u00E9 poruchy a reakce v m\u00EDst\u011B aplikace \nM\u00E9n\u011B \u010Dast\u00E9: astenie, \u00FAnava\nVy\u0161et\u0159en\u00ED\nM\u00E9n\u011B \u010Dast\u00E9: zv\u00FD\u0161en\u00ED hladiny mo\u010Doviny v\u00A0krvi, zv\u00FD\u0161en\u00ED hladiny kreatininu\nVe studii EPHESUS bylo zaznamen\u00E1no \u010D\u00EDseln\u011B v\u00EDce p\u0159\u00EDpad\u016F c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u star\u0161\u00EDch pacient\u016F (> 75 let v\u011Bku). Nicm\u00E9n\u011B v incidenci c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u t\u00E9to v\u011Bkov\u00E9 kategorie nebyl statisticky v\u00FDznamn\u00FD rozd\u00EDl mezi skupinou pacient\u016F l\u00E9\u010Den\u00FDch\u00A0eplerenonem (30) a skupinou u\u017E\u00EDvaj\u00EDc\u00ED placebo (22).\n"@cs . . . . . . "4.8\tNe\u017E\u00E1douc\u00ED \u00FA\u010Dinky"@cs . "004.008" .